Study Comparing JNJ-79635322 and Teclistamab for Multiple Myeloma
This study is comparing two treatments, JNJ-79635322 and Teclistamab, for people with multiple myeloma (a type of blood cancer) that has come back or is no longer responding to treatment. Both JNJ-79635322 and Teclistamab are bispecific antibodies, meaning they are designed to target specific cells. To join, you must be at least 18 years old, have a confirmed diagnosis of multiple myeloma, and have measurable disease. You also need to have received at least three prior treatments, including a proteasome inhibitor and an immunomodulatory drug. The study will look at how many people respond to the treatments and how long people live without their cancer getting worse. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 400 participants. It is comparing two different drug treatments.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 5 years and 7 months to assess overall response and progression-free survival.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
At a glance
Conditions
Where it's being run
144 sites across 39 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall ResponseUp to 5 years and 7 months
Overall response is defined as having achieved partial response (PR) or better, according to the international myeloma working group (IMWG) response criteria, as assessed any time after first administration of study treatment, but prior to progression of disease (PD) or subsequent antimyeloma therapy.
- Progression-Free Survival (PFS)Up to 5 years and 7 months
PFS is defined as the duration from the date of randomization to either progressive disease (PD) or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.